When Yang Wu peered through the super-resolution microscope at nasal cells from patients with rare genetic mutations, he saw something startling: a tangled, overgrown mesh of F-actin strangling the base of once-graceful cilia—tiny hair-like structures that should rhythmically sweep mucus and pathogens from the airways. These cilia, in patients with mutations in the RPGR gene, were sparse, stunted, and barely moving. Wu, part of Professor Zhen Liu’s team at The Hong Kong University of Science and Technology (HKUST), was unraveling the mystery of why some people with RPGR mutations develop primary ciliary dyskinesia (PCD), a rare respiratory disease marked by chronic lung infections, bronchiectasis, and sinusitis. While RPGR’s role in retinal degeneration is well known, its impact on motile cilia has remained elusive—until now.
This discovery matters because PCD is often underdiagnosed and highly variable in presentation. Not everyone with RPGR mutations develops respiratory symptoms, leaving families and doctors in the dark about who is at risk. By studying nasal multiciliated cells from 32 patients across Canada and using CRISPR-engineered models, the HKUST team identified a precise mechanism: RPGR loss leads to abnormal accumulation of F-actin at the cell’s apical surface, disrupting the organization and beating of cilia. Using advanced imaging, they revealed that this dense actin mesh physically impedes cilia formation and coordination—like vines overtaking a windmill.
The breakthrough came when researchers treated the cells with agents that disrupt F-actin. Suddenly, cilia began to regrow, lengthen, and regain movement. This reversal suggests not only a diagnostic pathway—using F-actin patterns as a biomarker—but also a potential therapeutic strategy. The study, published in the Journal of Clinical Investigation, is the first to link RPGR directly to actin regulation in motile cilia, opening a new front in the fight against rare ciliopathies.
For patients who’ve endured years of misdiagnoses and recurring infections, this work offers tangible hope. The collaboration between HKUST and pediatric hospitals in Canada—Hospital for Sick Children and BC Children’s Hospital—ensures the findings are rooted in real clinical data. With no cure currently available for PCD, the possibility of targeted treatments that restore ciliary function is transformative. As research moves toward animal models and potential drug screening, the path forward is clearer: untangle the actin, and the cilia may start beating again.
In a world where rare diseases often slip through the cracks, this study proves that with the right tools—and a little molecular detective work—answers can emerge from the smallest structures in our cells.